Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03176693 · ClinicalTrials.gov registry record · Phase 3
Preoperative Alpha Blockade for Pheochromocytoma
A Phase 3 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 3
- Development phase
- 39
- Enrollment target
NCT03176693 is a Phase 3 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 39 participants.
The verdict
NCT03176693, a Phase 3 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 39 participants
- Enrollment target
Study Summary
Pheochromocytoma is a rare, catecholamine (ex. adrenaline) secreting tumor that requires preoperative alpha blockade to minimize intraoperative hemodynamic instability, thereby reducing intra- and postoperative morbidity and mortality. Phenoxybenzamine is a non-selective alpha blocker that is significantly more expensive and is associated with increased adverse effects in comparison with selective alpha blockers such as doxazosin. Retrospective studies show minimal differences in hemodynamic instability and no differences in postoperative morbidity and mortality between selective vs. non-selective alpha blockers. This study is a randomized controlled trial that will compare hemodynamic instability, morbidity, mortality, cost, and quality of life between patients blocked with phenoxybenzamine vs. doxazosin.
Interventions
- DRUG Doxazosin
- DRUG Phenoxybenzamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2017-05-05 |
| Est. Completion | 2021-10-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03176693
The ClinicalTrials.gov registry entry for NCT03176693 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Doxazosin is the first listed.
NCT03176693 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03176693 about?
NCT03176693 is a clinical study titled "Preoperative Alpha Blockade for Pheochromocytoma". Pheochromocytoma is a rare, catecholamine (ex. adrenaline) secreting tumor that requires preoperative alpha blockade to minimize intraoperative hemodynamic instability, thereby reducing intra- and postoperative morbidity and mortality. Phenoxybenzamine is a non-selective alpha blocker that is signif...
What is the current status of trial NCT03176693?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 39 participants. The study started on 2017-05-05. Estimated completion is 2021-10-10.
What interventions are being tested in trial NCT03176693?
The interventions under investigation include: Doxazosin (DRUG), Phenoxybenzamine (DRUG).
Who is sponsoring clinical trial NCT03176693?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.